Amy Goodman of Democracy Now, interviews Rep. Raul Grijalva (D-AZ), a co-chair of the Congressional Progressive Caucus, regarding a Robust Public Option:
AMY GOODMAN: Congress member Grijalva, I also want to ask you about Senate Finance Committee Chair Max Baucus and his close ties to the healthcare industry. […]
REP. RAUL GRIJALVA: I think the product that has come out from his committee and himself, I really believe that it has no legitimacy in this debate. It’s an insider product. It’s there to protect the industry. It is not there to try to look for that middle ground. He is key in holding up deliberations, has been key in trying to work on a consensus, but everything you see in his legislation had to be approved by the industry before it became part of the plan. So I don’t think it’s legitimate.
[…] I consider Senator Baucus’s proposal to be essentially an insider trader move to protect an industry and really doesn’t have validity at all, both political validity or content validity.